Evolution of angiogenesis following anthracycline-based neoadjuvant chemotherapy in breast cancer;Efecto de la quimioterapia neoadyuvante con antraciclinas en la angiogenia del cáncer de mama

Medicina Clinica

Volumn 130, Issue 19, 2008, Pages 721-725

  Baena Cañada, José M ^a   Palomo González, María J ^a   Arellano, Esperanza Arriola ^a   Añón Requena, María J ^a   Rodríguez, Encarnación Benítez ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Angiogenesis; Breast neoplasms; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45249117666     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13121075     Document Type: Article

References (26)

1. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer. 1988;62:2507-16.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol. 1997;15:2483-93.
3. Van der Hage JA, Van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-37.
4. Insa A, Chirivella I, Lluch A. Tratamiento neoadyuvante del cáncer de mama operable. Med Clin (Barc). 2006;126:295-303.
5. Folkman J. What is the evidence that tumours are angiogenesis dependent. J Natl Cancer Inst. 1990;82:4-6.
6. Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer. 1999;85:1996-2000.
7. Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, et al. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res. 2002;8:1816-21.
8. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J. Is a histological section representative of whole tumour vascularity in breast cancer? Br J Cancer. 1997;76:40-3.
9. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-9.
10. Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G, et al. Chemotherapy and angiogenesis in advanced cancer: vascular endotelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int J Biol Markers. 2000;15:308-11.
11. Fersis N, Smyczek-Gargya B, Armeanu S, Gagulic E, Pantic L, Relakis K, et al. Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. Eur J Gynaecol Oncol. 2004;25:45-50.
12. th ed. Philadelphia: Lippinott-Raven; 1997.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
14. Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domíngez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am. 1988;4:125-31.
15. Honkoop AH, Van Diest PJ, De Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1988;77:621-6.
16. Honkoop AH, Pinedo HM, De Jong J, Verheul HM, Linn SC, Hoekman K, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol. 1997;107:211-8.
17. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res. 2000;6:139-46.
18. Hansen S, Sorensen FB, Vach W, Grabau DA, Bak M, Rose C. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology. 2004;44:428.
19. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signalling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59:4770-5.
20. Ioannis AA, Kwock R, Avramis V. Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukaemia T-cell lines. Anticancer Res. 2001;21:2281-6.
21. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999;14: 31-6.
22. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999;10:707-13.
23. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer. 2001;84:1354-62.
24. Marson LP, Kurian KM, Miller WR, Dixon JM. The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res. 2001;66:9-15.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;12:883-93.
26. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007;7:327-31.